There has been a flood of new products and a rush by companies to get new infection control products on the market since last summer, when the Centers for Medicare and Medicaid Services (CMS) passed a rule it will no longer reimburse healthcare facilities for preventable hospital-acquired infections (HAIs) starting in October 2008.

Medrad hopes to thrust new life into molecular imaging with its 510(k) pending FDG-PET power injector system called Intego, designed to promote greater accuracy in dose injection and which reportedly reduces radiation exposure related to FDG-handling by 40 percent.

The Deficit Reduction Act of 2005 (DRA) has left its mark on hospitals and outpatient imaging center operators. There is no denying that the imaging industry has changed forever. Some may think that the 10 percent of operators on the brink of bankruptcy or in default on payments to finance vendors is a mere market correction for years of overgrowth. But do the math.